First Stage Investor

NowRx Facing “Unprecedented” Demand

NowRx Facing “Unprecedented” Demand
When we first recommended NowRx to you in July 2018, its valuation was $20 million. Last November, we recommended you invest in the company again at a $65 million valuation — a more than 3X increase on your original investment price. We were impressed by its execution and…
Early Investing

First Stage Investor

Sign up to view this First Stage Investor article

Become a smarter investor! Discover new investment opportunities and get the latest market research, trends and analysis in startups, crypto and cannabis.

Top Posts on Early Investing